Apellis Pharmaceuticals Q2 EPS $(1.02) Beats $(1.35) Estimate, Sales $94.97M Beat $71.72M Estimate
Portfolio Pulse from Benzinga Newsdesk
Apellis Pharmaceuticals reported Q2 earnings per share (EPS) of $(1.02), beating the analyst consensus estimate of $(1.35) by 24.44%. This is a 30.14% increase over losses from the same period last year. The company also reported quarterly sales of $94.97 million, beating the analyst consensus estimate of $71.72 million by 32.42%. This is a 481.85% increase over sales from the same period last year.
July 31, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apellis Pharmaceuticals reported better than expected Q2 earnings and sales, which could positively impact the stock price.
Apellis Pharmaceuticals reported Q2 earnings and sales that beat analyst estimates. This is generally seen as positive news and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100